Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

2013 Archived Content
Second Annual

Point-of-Care Diagnostics

Innovation for the Future of Personalized Healthcare


Day 1 | Day 2 | Download Brochure | View TRICON Attendees 

In today's rapidly evolving diagnostics landscape, innovation is essential.  While point-of-care testing has the potential to streamline healthcare and improve clinical outcomes, technology developers, regulators, and clinicians must be creative to translate this potential into a reality. The second annual Point-of-Care Diagnostics symposium will provide a comprehensive overview of the point-of-care testing landscape, from novel technologies to reimbursement and regulatory approval.  Physicians will offer their perspective on point-of-care adoption in the clinical setting as well as in the global health environment, and the actual economic impact of point-of-care tests will be debated. This symposium will highlight breakthroughs, solutions, and next steps for making rapid testing for rapid intervention the future of personalized healthcare.

Monday, February 11

7:30 am Registration and Morning Coffee

8:25 Chairperson’s Opening Remarks


The Poc Testing Landscape: Intro Session 

8:30 How Pharma, Point-of-Care, & Molecular Diagnostics Will Work Together Comfortably

Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies

Peter S. Miller, COO, Genomic Healthcare Strategies

For decades, pharma business models have been reasonably static.The industry has done well; the blockbuster model has paid off; and hard times have been dealt with through consolidation, new research models/outsourcing research, and layoffs.This session will discuss the new problems and opportunities facing pharma caused by molecular medicine and the increased information required by doctors, payors, labs, patients, and institutions.

  • The impact of molecular diagnostics on pharma business models
  • Information needs of other participants
  • Where companion diagnostics will fit in
  • Effects on business models of point-of-care instruments
  • How it will all fit together

10:00 Coffee Break with Exhibit and Poster Viewing


Innovation and Diversity in Poc 

10:30 KEYNOTE PRESENTATION: P4 Medicine:A Platform for Diagnostic Assessment in the New World of Medicine

Clay Marsh, M.D., Executive Director, Center for Personalized Health Care; Vice Dean and Senior Associate Vice President, Research, College of Medicine; Professor, Internal Medicine, Pulmonary, Allergy, Critical Care and Sleep Medicine; Director, Center for Critical Care and Respiratory Medicine, Ohio State University Medical Center

This talk will help attendees understand the rational for transitioning medicine delivery from therapeutics to diagnostic focus, the definition of Wellness and how diagnostic capabilities might impact this field, and what is meant by precision medicine.

11:00 PANEL DISCUSSION: POC Products for Diverse Settings

Moderator: Peter S. Miller, COO, Genomic Healthcare Strategies

Panelists: David Steinmiller, COO, OPKO Diagnostics

Richard Gill, Ph.D., Director & CEO, TruTouch Technologies, Inc.

Shuqi Chen, Ph.D., CEO, IQuum, Inc.

12:00 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own


In the Clinic and Around the World 

1:25 Chairperson’s Remarks

1:30 Clinical and Economic Impact of Point-of-Care Testing

Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic Medical Center

POCT tends to be more expensive and more complex to manage in the hospital setting than tests on automated central laboratory platforms. POCT, on the other hand, can offer shorter turnaround times and convenience, and might impact outcomes. Proposed new programs should be evaluated for clinical benefit, quality of the results, potential pre- and post-analytical errors, and added costs such as implementation and training, maintenance, quality control, information technology, and the physician, nurse, and medical technologist time. The talk reviews the economy of POCT in the context of recent technological advancements and the changing healthcare environment, and highlights examples of clinical applications.

2:00 Technology Developer Perspective on POC in the Clinic

John McDonough, CEO & President, T2 Biosystems

This talk will focus on the challenges of developing diagnostic technologies for use in the point-of-care setting.  The talk will highlight the key requirements for driving market adoption including the types of diagnostic tests that are needed at the point-of-care, how tests must compare to central lab tests and ease of use requirements including the need for CLIA Waiver. The discussion will include a review the reasons why diagnostic testing in the point-of-care is poised for rapid growth and the technological and environmental challenges that could continue to limit adoption. 

2:30 Sophisticated Point-of-Care Diagnostic Devices based on 2D Paper Networks

Barry R. Lutz, Ph.D., Research Assistant Professor, Bioengineering, University of Washington

Two-dimensional paper networks (2DPNs) can perform complex chemical processes, but a far lower cost than conventional microfluidic or macrofluidic systems. We lead two ongoing “demonstration projects”.  NIH supports development of a device to perform more sensitive and multiplexed immunoassays based on chemical signal amplification. DARPA supports development of isothermal nucleic acid amplification in a fully-disposable paper-based format.

3:00 Refreshment Break with Exhibit and Poster Viewing

3:30 Implementation of Molecular Point-of-Care HIV-1 Diagnostics in Resource-Limited Settings

Marco L. Schito, Ph.D. (contractor), Henry M. Jackson Foundation, Vaccine Clinical Research Branch, DAIDS, NIAID, NIH

Despite the need to strengthen existing laboratory infrastructure, there are clear diagnostic needs where conventional laboratory support is insufficient.  Even with the advantages of near-patient testing, developers and implementers must also consider the environment where the assay is deployed, the technical skill of the operator, and balance the gains by assessing costs beyond the instrument and cartridges. 

4:00 PANEL DISCUSSION: How Will POC Save Money?

Moderator: Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies

Panelists: Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics, Immunology & Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic Medical Center

John McDonough, CEO & President, T2 Biosystems

5:00 Breakout Discussions

6:00 Close of Day

Day 1 | Day 2 | Download Brochure